James F. Howard Jr., MD - Identifying Myasthenia Gravis and Assessing Patients’ Response to Treatment to Improve Outcomes

Go online to PeerView.com/PAF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Conventional treatments (eg, corticosteroids, azathioprine, cyclosporine) are broadly immunosuppressive, do not target pathogenic IgG autoantibodies, often provide insufficient symptom relief, and are associated with significant side effects, leaving patients with substantial disease and treatment burden. Fortunately, advances in the understanding of MG pathogenesis are leading to the development of new therapeutics such as Fc receptor modulators and complement inhibitors that more selectively address the underlying disease process. Test your knowledge on this rare disease through this question-based activity. Upon completion of this activity, participants should be better able to: Recognize the range of signs and symptoms associated with myasthenia gravis (MG) to expedite an accurate diagnosis; Identify patients whose MG is not adequately controlled on their current treatment regimen; and Explain why and how to implement use of Myasthenia Gravis Activities of Daily Life (MG-ADL) in clinical care